Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The first patient has been dosed using new drug PORT-2 in Oxford, which hopes to improve treatment options for melanoma and Non-Small Cell Lung Cancer (NSCLC) and resensitise patients with checkpoint therapy-resistant tumours

Medication being administered to a patient via IV

The IMP-MEL clinical trial has begun with its first patient being dosed with the new drug PORT-2 today in Oxford. The Oxford-led study is investigating the tolerability and efficacy of PORT-2, a drug that was developed to target iKT and trigger a cancer-specific B and T-cell response to tumours.

The IMP-MEL study is expected to enroll 100 patients in Oxford and other centres, and will evaluate PORT-2 both as a monotherapy and in combination with approved PD-1 inhibitor drug Keytruda in the treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC).

Read the full story on the Oxford Cancer website.

Similar stories

What’s your sound barrier? New study finds nearly one in five people in the UK find everyday sounds intolerable

Researchers from King’s College London and University of Oxford have shown that 18.4 per cent of the general UK population report that certain sounds, such as loud chewing, and repetitive sniffing, cause a significant problem in their lives. The condition is known as misophonia.

Misophonia: nearly one in five UK adults have the condition causing extreme reactions to certain sounds

Many of us have sounds that we find to be annoying. But for some people, certain sounds actually trigger extreme reactions.

Any type of hormonal contraceptive may increase risk of breast cancer

An analysis of data by researchers at the Nuffield Department of Population Health’s Cancer Epidemiology Unit has shown that use of progestogen-only hormonal contraceptives is associated with a 20-30% higher risk of breast cancer. The results are published in PLOS Medicine.

Viewing self-harm images on the internet and in social media usually causes harm, according to new review

Clinical researchers have reviewed the international research evidence regarding the impact of viewing images of self-harm on the internet and in social media.

Can humans hibernate?

Illuminating new TEDx Talk from Professor of Sleep Physiology Vladyslav Vyazovskiy

Athena Swan Gold Award success for Nuffield Department of Primary Care Health Sciences

The award reflects the Department’s commitment to representation, progression and success for all. It acknowledges the innovative policies and practices developed across the department and the detailed action plans for improvement.